News archive

All the latest on Lundbeck

Keep updated on our latest corporate releases, press releases, and features.  

Filter within articles

Type Title Published
Press Release Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older Mar 13, 2025
Press Release Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan Mar 10, 2025
Corporate Release To the shareholders of H. Lundbeck A/S Feb 25, 2025
Corporate Release Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties Feb 21, 2025
Press Release Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA Feb 12, 2025
Corporate Release Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties Feb 5, 2025
Corporate Release Lundbeck Annual Report 2024 Feb 5, 2025
Corporate Release Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER) Feb 5, 2025
Corporate Release Lundbeck announces changes to the Board of Directors Feb 4, 2025
Press Release Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies Jan 30, 2025

Disclaimer

In order to comply with applicable regulation, press releases concerning a specific medicinal product are removed from our website within three weeks of publication. They can be retained upon request. Contact us here. 

More from Lundbeck

Investors

Detailed information related to Lundbeck’s financial performance. 

At a glance

A quick look into Lundbeck’s key facts and figures.

Organisation and ownership

Lundbeck is publicly listed with the Lundbeck Foundation as its main shareholder.